These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29665949)

  • 1. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children.
    Garcia-Prats AJ; Svensson EM; Weld ED; Schaaf HS; Hesseling AC
    Int J Tuberc Lung Dis; 2018 May; 22(5):15-23. PubMed ID: 29665949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
    Rashitov M; Franke M; Trevisi L; Bekbolatova G; Shalimova J; Eshmetov G; Bektasov S; LaHood A; Arlyapova N; Osso E; Yedilbayev A; Korotych O; Ciobanu A; Skrahina A; Mitnick CD; Seung K; Algozhin Y; Rich ML
    Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38833593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortened tuberculosis treatment regimens: what is new?
    Silva DR; Mello FCQ; Migliori GB
    J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities.
    McAnaw SE; Hesseling AC; Seddon JA; Dooley KE; Garcia-Prats AJ; Kim S; Jenkins HE; Schaaf HS; Sterling TR; Horsburgh CR
    Int J Infect Dis; 2017 Mar; 56():194-199. PubMed ID: 27955992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study.
    Fu L; Zhang X; Xiong J; Sun F; Weng T; Li Y; Zhang P; Li H; Yang Q; Cai Y; Liang H; Chen Q; Wang Z; Liu L; Chen X; Zhang W; Deng G
    Int J Infect Dis; 2023 Oct; 135():101-108. PubMed ID: 37567554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against
    Islam MM; Alam MS; Liu Z; Khatun MS; Yusuf B; Hameed HMA; Tian X; Chhotaray C; Basnet R; Abraha H; Zhang X; Khan SA; Fang C; Li C; Hasan S; Tan S; Zhong N; Hu J; Zhang T
    Front Med (Lausanne); 2023; 10():1304857. PubMed ID: 38274444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant tuberculosis in children: A practical update on epidemiology, diagnosis, treatment and prevention.
    Gaensbauer JT; Dash N; Verma S; Hall DJ; Adler-Shohet FC; Li G; Lee G; Dinnes L; Wendorf K
    J Clin Tuberc Other Mycobact Dis; 2024 Aug; 36():100449. PubMed ID: 38757115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community engagement for paediatric MDR-TB clinical trials: principles to support ethical trial implementation.
    Hoddinott G; Staples S; Brown R; Simwinga M; Mubekapi-Musadaidzwa C; Hesseling AC; Hendricks G; De Koker P; McKenna L
    Int J Tuberc Lung Dis; 2018 May; 22(5):40-45. PubMed ID: 29665952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis.
    Jeyakumar SM; Bhui NK; Singla N; Vilvamani S; Mariappan MV; Padmapriyadarsini C; Bhatnagar AK; Solanki R; Sridhar R
    Ther Drug Monit; 2023 Dec; 45(6):754-759. PubMed ID: 37296501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs.
    Huynh J; Marais BJ
    Ther Adv Infect Dis; 2019; 6():2049936119864737. PubMed ID: 31367376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
    Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofazimine for the treatment of tuberculosis.
    Stadler JAM; Maartens G; Meintjes G; Wasserman S
    Front Pharmacol; 2023; 14():1100488. PubMed ID: 36817137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-shortening regimens for tuberculosis: updates and future priorities.
    Saluzzo F; Adepoju VA; Duarte R; Lange C; Phillips PPJ
    Breathe (Sheff); 2023 Sep; 19(3):230028. PubMed ID: 37830101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Ali AM; P Solans B; Hesseling AC; Winckler J; Schaaf HS; Draper HR; van der Laan L; Hughes J; Fourie B; Nielsen J; Wiesner L; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0079423. PubMed ID: 38112526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region.
    Migliori GB; Korotych O; Achar J; Ciobanu A; Dravniece G; Germanovych M; Gurbanova E; Hovhannesyan A; Khachatryan N; Kuksa L; Lomtadze N; Rich ML; Skrahina A; Yedilbayev A
    IJTLD Open; 2024 Mar; 1(3):103-110. PubMed ID: 38966407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life use of delamanid: results from the European post-authorisation safety study.
    Schönfeld N; Barkane L; Davoliene I; Danilovits M; Miliauskas S; Ader F; Kon OM; Lange C; Duvignaud A; Heiss-Neumann M; Hittel N; Lazarević N; Knebel I; Martin A; Eschenbach B; van Heumen E; George V
    IJTLD Open; 2024 Jun; 1(6):274-278. PubMed ID: 39021446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Holistic acceptability of an adult levofloxacin formulation in children and adolescents on a tuberculosis preventive treatment trial.
    Purchase SE; Wademan DT; Tshetu NL; Rafique M; Hoddinott G; Seddon JA; Schaaf HS; Hesseling AC
    PLOS Glob Public Health; 2024; 4(7):e0003381. PubMed ID: 38968182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives.
    Suresh S; Fatma Begum R; Singh S A; Vellapandian C
    Curr Pharm Biotechnol; 2024 Jan; ():. PubMed ID: 38310450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can oral second-line anti-tuberculosis medications be administered to an extremely preterm neonate?
    Ngo TT; Lau C
    Eur J Hosp Pharm; 2024 Jul; ():. PubMed ID: 39002972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.